Keya Medical Technology Co.,Ltd.

Keya Medical is an international medical technology company founded in 2016, headquartered in Beijing with offices in Seattle, Shanghai, and Shenzhen. The company specializes in deep learning-based AI solutions for non-invasive disease diagnosis and treatment, with primary focus on cardiovascular care. Keya Medical develops AI-enabled diagnostic devices that enhance efficiency, accuracy, and precision in healthcare across cardiology, neurology, pulmonology, pathology, and surgery. The flagship product, DEEPVESSEL FFR, is a CT-derived fractional flow reserve (CT-FFR) analysis software that received FDA clearance (2022), CE marking (2018), NMPA approval (2020), and HSA certification (2023). This non-invasive tool reduces unnecessary invasive testing, improves patient safety, and lowers cardiovascular diagnostic costs. The company has secured over $111.74 million in funding and holds 11 registered patents related to artificial neural networks and medical imaging. Keya Medical established the first AI diagnostic laboratory and maintains collaborations with hospitals and key opinion leaders globally.